Synthetic FXR agonists including GW4064, INT-747, PX-102, FXR-450, and their analogs are under development for treating dyslipidemia, diabetes, primary biliary cirrhosis (PBC), and nonalcoholic steatohepatitis (NASH)11, 12. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.